- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Codex Labs Partners With Matthew Zachary To Advance Patient-Centered Skincare Solutions For The Cancer Community
Codex Labs expands its mission to support cancer patients with targeted supplements and gentle topicals designed for compromised skin.
Published on Feb. 22, 2026
Got story updates? Submit your updates here. ›
Codex Labs, a biotech skincare company, has announced a partnership with patient rights activist Matthew Zachary. Zachary will serve as a brand ambassador, helping to introduce Codex Labs' skin-gut-brain-microbiome solutions to the cancer community and advance access to their Decode.Me teledermatology platform for patients undergoing treatment. The partnership signifies a major step in Codex Labs' mission to support cancer patients struggling with skin health issues.
Why it matters
This partnership aims to provide much-needed support and effective, clinically backed skincare solutions to cancer patients, who often face significant skin health challenges during treatment. Zachary's advocacy work and platform will help raise awareness and improve access to these patient-centered offerings.
The details
Codex Labs is expanding its product line to include targeted supplements and gentle topicals designed to support skin health for cancer patients undergoing chemotherapy, radiation, and other treatments. These offerings take an inside-out approach, supporting the skin-gut-brain-microbiome axis with evidence-based, plant-powered formulations. Zachary, the founder of the nonprofit Stupid Cancer and author of 'We the Patients,' will share information about Codex Labs' products and Decode.Me telederm platform with his audiences, providing science-backed and accessible skincare solutions.
- Codex Labs and Matthew Zachary announced the partnership on February 18, 2026.
- Zachary's book 'We the Patients' is set to be published in May 2026.
The players
Codex Labs
A biotech skincare company focused on microbiome-friendly solutions, headquartered in Silicon Valley and led by serial entrepreneur Dr. Barb Paldus.
Matthew Zachary
An American patient rights activist, the founder of the nonprofit Stupid Cancer, and the author of the upcoming book 'We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.'
Dr. Barbara Paldus
The founder and CEO of Codex Labs.
Nina King
The Community Manager at Codex Labs.
What they’re saying
“Codex Labs is honored to partner with Matthew Zachary as an ambassador to help introduce our skin-gut-brain-microbiome solutions to the cancer community and advance access to our Decode.Me teledermatology platform for patients undergoing chemotherapy, radiation, and other life-altering treatments.”
— Dr. Barbara Paldus, Founder and CEO of Codex Labs
“Matthew is widely respected for his leadership in patient advocacy and for bringing much-needed insight and innovation to improving the healthcare system.”
— Nina King, Community Manager at Codex Labs
What’s next
Zachary's book 'We the Patients' is set to be published in May 2026, which will further amplify his advocacy work and the partnership with Codex Labs.
The takeaway
This partnership between Codex Labs and Matthew Zachary represents a significant step in providing much-needed, patient-centered skincare solutions and support for the cancer community, addressing a critical gap in the healthcare system.
San Jose top stories
San Jose events
Mar. 11, 2026
San Jose Barracuda vs. San Diego GullsMar. 12, 2026
Phil HanleyMar. 13, 2026
Phil Hanley




